Demographic and clinical data of seven patients with MIE
| Patient | Age/Sex | Underlying Disease | Drug Dosage (g)/Duration (days) | Symptoms | Medication Duration Before Symptom Development (days) | Time to Clinical Improvement after Drug Discontinuation (days) | Duration Between Symptom Onset and Initial MRI (days) | Duration Between Drug Discontinuation and Follow-Up MRI (days)a |
|---|---|---|---|---|---|---|---|---|
| 1 | 49/M | Crohn disease | 135/90 | Weakness of extremities, dysarthria, gait disturbance | 52 | 10 | 38 | – |
| 2 | 70/M | Brain abscess, LC | 57/38 | Weakness of extremities, dysarthria | 22 | 7 | 7 | 14 |
| 3 | 64/M | Intraabdominal abscess | 37.5/25 | Dysarthria, gait disturbance, visual blurring | 17 | 7 | 17 | 17 |
| 4 | 54/M | Spontaneous bacterial peritonitis, LC | 49.5/33 | Dysarthria, confusion | 15 | 5 | 21 | – |
| 5 | 71/M | DM foot, CRF | 66/44 | Dysarthria, gait disturbance | 37 | 4 | 3 | 34 |
| 6 | 55/M | Ischemic colitis, LC | 21/14 | Dysarthria, gait disturbance, tingling sensation of both extremities | 11 | 7 | 3 | 15 |
| 7 | 61/F | Pseudo-membranous colitis | 40.5/27 | Dysarthria, gait disturbance | 24 | 7 | 5 | – |
Note:—LC indicates liver cirrhosis; CRF, chronic renal failure; DM, diabetes mellitus.
a Follow-up MR imaging was not studied in 3 patients (patients 1, 4, and 7).